Corcept Therapeutics

YTD

ALL

Trade Corcept Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About CORT

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B.

CEO

Joseph K. Belanoff

CEOJoseph K. Belanoff

Employees

730

Employees730

Headquarters

Redwood City, California

HeadquartersRedwood City, California

Founded

1998

Founded1998

Employees

730

Employees730

CORT Key Statistics

Market cap

5.52B

Market cap5.52B

Price-Earnings ratio

56.86

Price-Earnings ratio56.86

Dividend yield

—

Dividend yield—

Average volume

950.19K

Average volume950.19K

High today

$51.65

High today$51.65

Low today

$46.19

Low today$46.19

Open price

$48.48

Open price$48.48

Volume

3.27M

Volume3.27M

52 Week high

$91.00

52 Week high$91.00

52 Week low

$28.66

52 Week low$28.66

Stock Snapshot

As of today, Corcept Therapeutics(CORT) shares are valued at $51.42. The company's market cap stands at 5.52B, with a P/E ratio of 56.86.

As of 2026-05-01, Corcept Therapeutics(CORT) stock has fluctuated between $46.19 and $51.65. The current price stands at $51.42, placing the stock +11.3% above today's low and -0.4% off the high.

Corcept Therapeutics(CORT) shares are trading with a volume of 3.27M, against a daily average of 950.19K.

During the past year, Corcept Therapeutics(CORT) stock moved between $28.66 at its lowest and $91.00 at its peak.

CORT News

Simply Wall St 3h

Is Corcept Therapeutics Pricing Make Sense After Recent Volatility In The Share Price

If you are wondering whether Corcept Therapeutics at around US$51.42 is attractively priced or already stretched, starting with a clear view of valuation can he...

Benzinga 10h

Corcept Therapeutics Pivotal Study Shows 87% Lower Death Risk

Corcept DAZALS Phase 2 Data Drives CORT Stock Move The DAZALS study revealed that patients treated with 300 mg of dazucorilant daily exhibited improved overall...

TipRanks 13h

Corcept Therapeutics price target raised to $88 from $73 at Piper Sandler

Piper Sandler raised the firm’s price target on Corcept Therapeutics (CORT) to $88 from $73 and keeps an Overweight rating on the shares following quarterly res...

Analyst ratings

71%

of 7 ratings

Buy

71.4%

Hold

28.6%

Sell

More CORT News

TipRanks 1d

Corcept Therapeutics Guides Higher on Lifyorli-Fueled Revenue Growth

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

TipRanks 4d

Analyst Reiterates Buy on Corcept, Sees Upside with Unchanged $110 Target as Korlym Growth Set to Re-Accelerate and Lifyorli Ramps

Corcept Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Edward Nash from Canaccord Genuity maintained a Buy r...

People also own

Based on the portfolios of people who own CORT. This list is generated using Robinhood data, and it’s not a recommendation.

Novo Nordisk

Broadcom

Palantir Technologies

Robinhood Markets

Gilead Sciences

Spotify

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.